{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:09:13Z","timestamp":1780463353856,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The remarkable cardiorenal benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have positioned these agents as cornerstone therapies for diabetic kidney disease (DKD). However, theoretical concerns regarding glycosuria-mediated effects on tissue perfusion have left clinicians uncertain about their safety in patients with active wounds. We conducted a prospective cohort study to characterize wound healing outcomes in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 2018 and December 2023, we prospectively enrolled 247 adults with type 2 diabetes mellitus, estimated glomerular filtration rate (eGFR) of 30\u201390 mL\/min\/1.73m\u00b2, and wounds requiring medical attention at a tertiary wound care center. Participants receiving SGLT2 inhibitors (dapagliflozin, empagliflozin, or canagliflozin) for \u226530 days were matched 1:1 with unexposed controls using propensity scores derived from 15 baseline covariates. The primary endpoint was the time to complete epithelialization; secondary endpoints included wound infection and renal progression at six months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following propensity score matching, 204 patients (102 per cohort) with excellent covariate balance (all standardized mean differences &amp;lt;0.10) were analyzed. Wound healing trajectories were virtually identical between the cohorts: median healing time was 33 days (interquartile range [IQR]: 22\u201352) with SGLT2 inhibitors versus 34 days (24\u201362) in controls (adjusted hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.82\u20131.42; p=0.594). No statistically significant difference in infection rates was observed (38.2% vs. 32.4%; unadjusted p=0.464; adjusted p=0.310). During the six-month follow-up period, no renal progression events were observed among SGLT2 inhibitor users (0% vs. 5.9%; p=0.029) and demonstrated superior eGFR preservation (\u22122.3\u00a0\u00b1\u00a03.8 vs. \u22125.5\u00a0\u00b1\u00a04.5 mL\/min\/1.73m\u00b2; p&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No evidence of impaired wound healing or increased infection risk was observed with SGLT2 inhibitor therapy in patients with DKD; however, the anticipated nephroprotective benefits were preserved during the six-month follow-up period. These findings argue against the withholding of these beneficial agents in patients with concurrent wounds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1793030","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:54:57Z","timestamp":1780462497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Rong-rong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science","place":["Xiangyang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyue","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science","place":["Xiangyang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science","place":["Xiangyang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science","place":["Xiangyang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.10.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","author":"Herrington","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.33590\/emjdiabet\/201014","article-title":"New guideline for diabetes management in chronic kidney disease: A meet-the-expert session","volume":"8","year":"2020","journal-title":"EMJ Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf044","article-title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know","volume":"82","author":"Awdishu","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40278-020-82825-x","article-title":"US FDA removes boxed warning from canagliflozin products","volume":"1820","year":"2020","journal-title":"React Wkly"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diabetes Vasc Dis Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.70713","article-title":"Pathophysiology of wound development and chronicity in renal disease: A narrative review","volume":"22","author":"Sandepudi","year":"2025","journal-title":"Int Wound J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.283887","article-title":"Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway","volume":"593","author":"Garc\u00eda-J\u00e9rez","year":"2015","journal-title":"J Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.123.321752","article-title":"Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease","volume":"132","author":"Baaten","year":"2023","journal-title":"Circ Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051076","article-title":"Diabetic foot ulcers: Pathophysiology, immune dysregulation, and emerging therapeutic strategies","volume":"13","author":"Dawi","year":"2025","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.11491116","article-title":"Diabetic kidney disease","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2023.10578","article-title":"Diabetic foot ulcers","volume":"330","author":"Armstrong","year":"2023","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0043","article-title":"Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers","volume":"46","author":"McDermott","year":"2022","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15364","article-title":"ffect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Bantounou","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01897-2","article-title":"The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","volume":"22","author":"Werkman","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Internal Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00125-006-0491-1","article-title":"High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study","volume":"50","author":"Prompers","year":"2006","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1067-2516(96)80125-6","article-title":"Classification of diabetic foot wounds","volume":"35","author":"Lavery","year":"1996","journal-title":"J Foot Ankle Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity\u2010score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity\u2010score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis346","article-title":"2012 infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infectionsa","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7326\/m16-2607","article-title":"Sensitivity analysis in observational research: Introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Internal Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: The targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","article-title":"SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives","volume":"35","author":"Piperidou","year":"2020","journal-title":"J Hum Hypertens"},{"key":"B36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: Effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diabetes Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2015.11.011","article-title":"The effect of short-term hyperglycemia on the innate immune system","volume":"351","author":"Jafar","year":"2016","journal-title":"Am J Med Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1793030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:55:07Z","timestamp":1780462507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1793030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1793030"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1793030","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1793030"}}